Tag: a clinical-stage biotechnology company commercializing a novel vaccination platform
Vaxxas raises $34 million to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.
Featured Article
Navigating energy price volatility with predictive intelligence
Energy price volatility has become a structural feature of modern electricity markets rather than a temporary disruption. For energy-intensive manufacturers and large commercial operators, fluctuating wholesale prices are reshaping how energy costs are managed, making reactive approaches increasingly inadequate.
